Business
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
ATLANTA, February 19, 2025--Alzamend Neuro Announces Completion of Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials
About this update from Alzamend Neuro, Inc.
[{"type":"image","alt":"Tesla Head Coil (Tesla Dynamic Coils BV) Photo Courtesy of Alzamend Neuro, Inc. All rights reserved and proprietary, @2025 #Alzamend @Alzamend $Alzamend @LiProSal #LiProSal $LiProSal #MassachusettsGeneralHospital $MassachusettsGeneralHospital #Whole-brain_imaging $whole-brain_imaging #one-of-a-kind_head_coil $one-of-s-kind_head_coil (Photo: Business Wire)","displaySize":"","headline":null,"caption":"Tesla Head Coil (Tesla Dynamic Coils BV) Photo Courtesy of Alzamend Neuro, Inc. All rights reserved and proprietary, @2025 #Alzamend @Alzamend $Alzamend @LiProSal #LiProSal $LiProSal #MassachusettsGeneralHospital $MassachusettsGeneralHospital #Whole-brain_imaging $whole-brain_imaging #one-of-a-kind_head_coil $one-of-s-kind_head_coil (Photo: Business Wire)","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":340,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/1655b6ad2707e730a9cd411cd0e710f9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ohPgPVcJ9Ny6TNjia.r5Zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTkwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1655b6ad2707e730a9cd411cd0e710f9","width":340,"height":480}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1667,"height":346,"url":"https://media.zenfs.com/en/business-wire.com/a0bdea5c40d44d2624d6ae2cedde1bad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qBV_bfJMBSaUHpYgcuZP0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a0bdea5c40d44d2624d6ae2cedde1bad","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/EcSl7ti5MbutQefI3hTRNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a0bdea5c40d44d2624d6ae2cedde1bad","width":1200,"height":249}}},{"type":"list","items":[{"val":[{"type":"text","content":"Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy, Alzheimer’s disease, BD, MDD, and PTSD subjects","length":227,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":227,"olType":false},{"type":"text","content":"ATLANTA, February 19, 20...